{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:28:21Z","timestamp":1787311701932,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40256-026-00819-3","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:34:12Z","timestamp":1784982852000},"page":"657-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Sacubitril\/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2242-1274","authenticated-orcid":false,"given":"Munaza","family":"Riaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3299-8111","authenticated-orcid":false,"given":"Haesuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"819_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","volume":"31","author":"B Bozkurt","year":"2024","unstructured":"Bozkurt B, Ahmad T, Alexander K, Baker WL, Bosak K, Breathett K, et al. HF STATS 2024: heart failure epidemiology and outcomes statistics An updated 2024 report from the Heart Failure Society of America. J Card Fail. 2024;31:66\u2013116. https:\/\/doi.org\/10.1016\/j.cardfail.2024.07.001.","journal-title":"J Card Fail"},{"key":"819_CR2","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 Heart Disease and Stroke Statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347\u2013913. https:\/\/doi.org\/10.1161\/CIR.0000000000001209.","journal-title":"Circulation"},{"key":"819_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s12265-022-10220-5","volume":"15","author":"HM Salah","year":"2022","unstructured":"Salah HM, Verma S, Santos-Gallego CG, Bhatt AS, Vaduganathan M, Khan MS, et al. Sodium-glucose cotransporter 2 inhibitors and cardiac remodeling. J Cardiovasc Transl Res. 2022;15:944\u201356. https:\/\/doi.org\/10.1007\/s12265-022-10220-5.","journal-title":"J Cardiovasc Transl Res"},{"key":"819_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"819_CR5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","volume":"83","author":"M Maddox Thomas","year":"2024","unstructured":"Maddox Thomas M, Januzzi James L, Allen Larry A, Breathett K, Brouse S, Butler J, et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction. JACC. 2024;83:1444\u201388. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.024.","journal-title":"JACC"},{"key":"819_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"819_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial. J Am Coll Cardiol. 2021;77:1381\u201392. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.033.","journal-title":"J Am Coll Cardiol"},{"key":"819_CR8","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"key":"819_CR9","unstructured":"ENTRESTO (sacubitril\/valsartan) Tablets. In. Accessed on November 09, 2025."},{"key":"819_CR10","unstructured":"FDA. Highlights of Prescribing Information\u2014FARXIGA. In. Accessed on November 09, 2025."},{"key":"819_CR11","unstructured":"JARDIANCE\u00ae (empagliflozin) tablets, for oral use. In. Accessed on November 09, 2025."},{"key":"819_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/clc.24085","volume":"46","author":"X Mo","year":"2023","unstructured":"Mo X, Lu P, Yang X. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and meta-analysis. Clin Cardiol. 2023;46:1137\u201345. https:\/\/doi.org\/10.1002\/clc.24085.","journal-title":"Clin Cardiol"},{"key":"819_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2021.02.035","volume":"330","author":"F-C Hsiao","year":"2021","unstructured":"Hsiao F-C, Lin C-P, Tung Y-C, Chang P-C, McMurray JJV, Chu P-H. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: a multi-institutional study. Int J Cardiol. 2021;330:91\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2021.02.035.","journal-title":"Int J Cardiol"},{"key":"819_CR14","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000001426","author":"Y Huang","year":"2023","unstructured":"Huang Y, Fang C, Zhang Y, Ma L, Zhou H, Ye H. Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodium\u2013glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis. J Cardiovasc Med (Hagerstown). 2023. https:\/\/doi.org\/10.2459\/JCM.0000000000001426.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"819_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001111","author":"M Jim\u00e9nez-Blanco Bravo","year":"2021","unstructured":"Jim\u00e9nez-Blanco Bravo M, Valle A, Gay\u00e1n Ord\u00e1s J, del Prado D\u00edaz S, Cordero Pereda D, Morillas Climent H, et al. Safety and efficacy of the combination of sacubitril\/valsartan and SGLT2i in HFrEF patients (SECSI registry). J Cardiovasc Pharmacol. 2021. https:\/\/doi.org\/10.1097\/FJC.0000000000001111.","journal-title":"J Cardiovasc Pharmacol"},{"key":"819_CR16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10557-020-07099-2","volume":"35","author":"A Aimo","year":"2021","unstructured":"Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi CM, Passino C, et al. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther. 2021;35:1067\u201376. https:\/\/doi.org\/10.1007\/s10557-020-07099-2.","journal-title":"Cardiovasc Drugs Ther"},{"key":"819_CR17","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/ehf2.13313","volume":"8","author":"Y Yan","year":"2021","unstructured":"Yan Y, Liu B, Du J, Wang J, Jing X, Liu Y, et al. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8:2210\u20139. https:\/\/doi.org\/10.1002\/ehf2.13313.","journal-title":"ESC Heart Fail"},{"key":"819_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01081-2","volume":"15","author":"M-L Tsai","year":"2023","unstructured":"Tsai M-L, Lin Y, Lin M-S, Tsai T-H, Yang N-I, Wang C-Y, et al. Comparing angiotensin receptor\u2013neprilysin inhibitors with sodium-glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus. Diabetol Metab Syndr. 2023;15:110. https:\/\/doi.org\/10.1186\/s13098-023-01081-2.","journal-title":"Diabetol Metab Syndr"},{"key":"819_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089562","volume":"14","author":"K Tiwari","year":"2024","unstructured":"Tiwari K, Deora S, Choudhary R, Kaushik A, Dwivedi P, Singh S, et al. Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol. BMJ Open. 2024;14:e089562. https:\/\/doi.org\/10.1136\/bmjopen-2024-089562.","journal-title":"BMJ Open"},{"key":"819_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.122.009078","volume":"16","author":"BA Bates","year":"2023","unstructured":"Bates BA, Akhabue E, Nahass MM, Mukherjee A, Hiltner E, Rock J, et al. Validity of International Classification of Diseases (ICD)-10 diagnosis codes for identification of acute heart failure hospitalization and heart failure with reduced versus preserved ejection fraction in a national Medicare sample. Circ Cardiovasc Qual Outcomes. 2023;16:e009078. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.122.009078.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"819_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pds.4690","volume":"28","author":"P Bosco-Levy","year":"2019","unstructured":"Bosco-Levy P, Duret S, Picard F, Dos Santos P, Puymirat E, Gilleron V, et al. Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database. Pharmacoepidemiol Drug Saf. 2019;28:194\u2013200. https:\/\/doi.org\/10.1002\/pds.4690.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 1","key":"819_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/pds.2313","volume":"21","author":"JS Saczynski","year":"2012","unstructured":"Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):129\u201340. https:\/\/doi.org\/10.1002\/pds.2313.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"819_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/phar.2610","volume":"41","author":"M Riaz","year":"2021","unstructured":"Riaz M, Smith SM, Dietrich EA, Pepine CJ, Park H. Effectiveness of sacubitril\/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: a retrospective cohort study. Pharmacotherapy. 2021;41:710\u201321. https:\/\/doi.org\/10.1002\/phar.2610.","journal-title":"Pharmacotherapy"},{"key":"819_CR24","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/j.amjmed.2019.10.030","volume":"133","author":"AM Chamberlain","year":"2020","unstructured":"Chamberlain AM, Boyd CM, Manemann SM, Dunlay SM, Gerber Y, Killian JM, et al. Risk factors for heart failure in the community: differences by age and ejection fraction. Am J Med. 2020;133:e237\u201348. https:\/\/doi.org\/10.1016\/j.amjmed.2019.10.030.","journal-title":"Am J Med"},{"key":"819_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","volume":"6","author":"MA Brookhart","year":"2013","unstructured":"Brookhart MA, Wyss R, Layton JB, Sturmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6:604\u201311. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.113.000359.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"819_CR26","doi-asserted-by":"publisher","first-page":"1302811","DOI":"10.1155\/2021\/1302811","volume":"2021","author":"S Abd ElHafeez","year":"2021","unstructured":"Abd ElHafeez S, D\u2019Arrigo G, Leonardis D, Fusaro M, Tripepi G, Roumeliotis S. Methods to analyze time-to-event data: the Cox regression analysis. Oxid Med Cell Longev. 2021;2021:1302811. https:\/\/doi.org\/10.1155\/2021\/1302811.","journal-title":"Oxid Med Cell Longev"},{"key":"819_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13145","volume":"49","author":"M Brankovic","year":"2019","unstructured":"Brankovic M, Kardys I, Steyerberg EW, Lemeshow S, Markovic M, Rizopoulos D, et al. Understanding of interaction (subgroup) analysis in clinical trials. Eur J Clin Invest. 2019;49:e13145. https:\/\/doi.org\/10.1111\/eci.13145.","journal-title":"Eur J Clin Invest"},{"key":"819_CR28","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/aje\/kwab041","volume":"190","author":"T St\u00fcrmer","year":"2021","unstructured":"St\u00fcrmer T, Webster-Clark M, Lund JL, Wyss R, Ellis AR, Lunt M, et al. Propensity Score weighting and trimming strategies for reducing variance and bias of treatment effect estimates: a simulation study. Am J Epidemiol. 2021;190:1659\u201370. https:\/\/doi.org\/10.1093\/aje\/kwab041.","journal-title":"Am J Epidemiol"},{"key":"819_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","volume":"28","author":"J Malgie","year":"2023","unstructured":"Malgie J, Clephas PRD, Brunner-La Rocca HP, de Boer RA, Brugts JJ. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Heart Fail Rev. 2023;28:1221\u201334. https:\/\/doi.org\/10.1007\/s10741-023-10325-2.","journal-title":"Heart Fail Rev"},{"key":"819_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-021-01098-3","volume":"42","author":"YN Teo","year":"2022","unstructured":"Teo YN, Teo YH, Syn NL, Yoong CSY, Cheong AJY, Wee CF, et al. Comparing sacubitril\/valsartan against sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and network meta-analysis. Clin Drug Investig. 2022;42:1\u201316. https:\/\/doi.org\/10.1007\/s40261-021-01098-3.","journal-title":"Clin Drug Investig"},{"key":"819_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.754499","volume":"8","author":"D Pascual-Figal","year":"2021","unstructured":"Pascual-Figal D, Bayes-Genis A, Beltran-Troncoso P, Caravaca-Perez P, Conde-Martel A, Crespo-Leiro MG, et al. Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review. Front Cardiovasc Med. 2021;8:754499. https:\/\/doi.org\/10.3389\/fcvm.2021.754499.","journal-title":"Front Cardiovasc Med."},{"key":"819_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.892460","volume":"13","author":"NH Mustafa","year":"2022","unstructured":"Mustafa NH, Jalil J, Zainalabidin S, Saleh MSM, Asmadi AY, Kamisah Y. Molecular mechanisms of sacubitril\/valsartan in cardiac remodeling. Front Pharmacol. 2022;13:892460. https:\/\/doi.org\/10.3389\/fphar.2022.892460.","journal-title":"Front Pharmacol"},{"key":"819_CR33","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2024.13197","author":"B Chen","year":"2024","unstructured":"Chen B, Guo J, Ye H, Wang X, Feng Y. Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (review). Mol Med Rep. 2024. https:\/\/doi.org\/10.3892\/mmr.2024.13197.","journal-title":"Mol Med Rep"},{"key":"819_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632\u201344. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004.","journal-title":"JACC Basic Transl Sci."},{"key":"819_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A, Montecucco F, Carbone F, Camici GG, Luscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120:443\u201360. https:\/\/doi.org\/10.1093\/cvr\/cvae047.","journal-title":"Cardiovasc Res"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00819-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:45:52Z","timestamp":1787309152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00819-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00819-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest relevant to this paper to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study were derived from the Merative\u2122 MarketScan\n                      \u00ae\n                      Research Databases, which are deidentified and commercially licensed. Access to these databases requires a subscription and approval from the data provider. The analytical code used for this study is available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Florida Institutional Review Board approved the study.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: M.R., H.P. Data acquisition: H.P. Methodology: M.R., H.P. Visualization: M.R. Supervision: H.P. Formal analysis: M.R. Interpretation: M.R., S.M.S., D.E.W., E.A.D., H.P. Writing original draft: M.R. Writing review and editing: M.R., S.M.S., D.E.W., E.A.D., H.P.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}